Effect of Cortexin on neuroplasticity in multiple sclerosis
Observational study · 2009
- What was studied
- 20 adults with relapsing-remitting MS in stable remission; 7 men and 13 women, ages 27–43
- Main finding
- Depression and quality-of-life scores improved in an open MS cohort; the disability score did not change significantly.
Beck depression score · 17.6 ± 1.3 → 12.9 ± 1.4 points · Within-person change; 12 participants had depressive symptoms at baseline · After the treatment program · p<0.05 versus baseline
Reported findings and study design
Depression and quality-of-life scores improved in an open MS cohort; the disability score did not change significantly.
20 adults with relapsing-remitting MS in stable remission; two ten-day courses of 10 mg intramuscular Cortexin with a two-week interval; no control group.
Population or model 20 adults with relapsing-remitting MS in stable remission; 7 men and 13 women, ages 27–43
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Beck depression score | 17.6 ± 1.3 → 12.9 ± 1.4 points | Within-person change; 12 participants had depressive symptoms at baseline · After the treatment program · p<0.05 versus baseline |
| EQ-5D health score | 0.41 ± 0.07 → 0.73 ± 0.03 | Within-person change; higher score indicates better reported health · After treatment · p<0.05 versus baseline |
| EDSS disability | No significant change | Participants entered in remission with EDSS below 3 |
| Adverse events | None observed in 20 participants | Small, short open study; not a long-term safety estimate |
These results concern symptoms and quality of life in an uncontrolled cohort. Stable EDSS during a short remission-period study does not demonstrate remyelination or prevention of disease progression.
Source for these results ↗ · Reviewed 2026-11-01
Study limitations and source details
Study limitations
- Open prospective study without a control group, randomization or blinding.
- Participants were already in remission; stable EDSS does not demonstrate prevention of progression.
- No adverse events were observed in this small sample; safety and disease modification are not established.
Source details
Publisher article and Russian PDF
Publisher full-text results narrative and available tables checked on 1 November 2026
Sources checked
Citation
S. V. Kotov, T. I. Yakushina, V. Yu. Lizhdvoy. Effect of Cortexin on neuroplasticity in multiple sclerosis Effective Pharmacotherapy. Neurology and Psychiatry. 2009;(3):14–16